Supplemental_Tables1-2.docx (15.79 kB)

Supplementary Tables – Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives

dataset

posted on 07.03.2022, 08:55 by Figshare Future Science GroupFigshare Future Science Group, Suvina Amin, Sara M. Tolaney, M. Janelle Cambron-Mellott, Kathleen Beusterien, Martine C. Maculaitis, Emily Mulvihill, Reshma Shinde, Kimmie McLaurin

Supplemental Table 1. Study attrition: patients.

Supplemental Table 2. Study attrition: oncologists.

Funding

AstraZeneca

Merck Sharp and Dohme

History

Usage metrics

Read the peer-reviewed publication

Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives

Future Oncology

Keywords

Advanced breast cancer Metastatic breast cancer patient preferences oncologist preferences discrete choice experiment HER2 negative treatment goals Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Solid Tumours

Licence

CC BY-NC-ND 4.0